Unjoni Ewropea - Malti - EMA (European Medicines Agency)

theravia - hydroxycarbamide - anemija, sickle cell - aġenti antineoplastiċi - siklos huwa indikat għall-prevenzjoni tar-rikorrenti uġigħ kriżijiet vaso-okklusivi inklużi l-sindromu akut tas-sider f'pazjenti pedjatriċi u adulti li jsofru minn sintomatika tas-sickle cell syndrome.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

nova laboratories ireland limited - hydroxycarbamide - anemija, sickle cell - aġenti antineoplastiċi - il-prevenzjoni ta vaso-okklusivi komplikazzjonijiet tal-marda taċ-ċelluli sickle fil-pazjenti ta ' aktar minn 2 snin ta'età.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulanti, - besremi huwa indikat bħala monoterapija fl-adulti għat-trattament ta ' poliċitemija vera mingħajr sintomatika splenomegalija.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - aġenti antineoplastiċi - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (bħala fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - aġenti antineoplastiċi - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. poliċitemija vera (pv)jakavi huwa indikat għall-kura ta ' pazjenti adulti b'poliċitemija vera li huma reżistenti jew intolleranti għal hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.